Nuvation Bio reported third quarter 2026 total revenue of $45.0 million, significantly outperforming the analyst consensus of $34.4 million due to strong commercial adoption of its lead product and one-time collaboration milestones. The company reported a net loss of $41.9 million, or $0.12 per share, meeting analyst expectations exactly.
Key Highlights
- IBTROZI (taletrectinib) generated $27.5 million in net product revenue, reflecting 18% sequential growth over the prior quarter.
- New patient starts remained stable at approximately 160 despite a 15% contraction in the broader ROS1 tyrosine kinase inhibitor (TKI) market.
- Collaboration and license revenue reached $17.5 million, supported by a $5.0 million sales milestone from Innovent and $7.6 million in product supply revenue.
- The FDA approved a supplemental New Drug Application (sNDA) for IBTROZI four months ahead of schedule, updating the label to include a 49.7-month median duration of response.